| WelGrace Research Pharmaceuticals |
 | |  | |  |
 |
| |
 |
| |
 |
| |
 |
WelGrace Research Pharmaceuticals
is a specialty pharmaceutical business
unit. We develop select new products
and novel, high-quality and
differentiated formulations of existing
critical-care products to deliver
incremental patient benefit in the
management and treatment of
acute conditions.
WelGrace Research Pharmaceutical
unit collaborates with pharmaceutical
companies and biotechnology firms,
bringing the following core capabilities:
We have the expertise to develop specialty formulations that expand
the use of existing molecules and provide:
WelGrace Research Pharmaceuticals also develops innovative delivery
routes and systems for re-formulated products through proof of concept,
and forms alliances with commercial partners for the manufacture, sale
and distribution of such technology transfers. These delivery routes
and systems include:
At WelGrace Research Pharmaceuticals, our approach is to:
is a specialty pharmaceutical business
unit. We develop select new products
and novel, high-quality and
differentiated formulations of existing
critical-care products to deliver
incremental patient benefit in the
management and treatment of
acute conditions.
WelGrace Research Pharmaceutical
unit collaborates with pharmaceutical
companies and biotechnology firms,
bringing the following core capabilities:
- Rigorous market research and analysis
- Strong intellectual property positions/strategies
- Experienced, high-quality management
- Proven formulation and analytical technology approaches
We have the expertise to develop specialty formulations that expand
the use of existing molecules and provide:
WelGrace Research Pharmaceuticals also develops innovative delivery
routes and systems for re-formulated products through proof of concept,
and forms alliances with commercial partners for the manufacture, sale
and distribution of such technology transfers. These delivery routes
and systems include:
At WelGrace Research Pharmaceuticals, our approach is to:
- Develop products and technologies through proof of concept
- Identify shorter development and strategic regulatory pathways
- Improve safety and compliance through pre-clinical studies
- License products to pharmaceutical industry partners for sales and
marketing - Form alliances for strategic co-development
- Minimize additional clinical investigations
|
|
For more information, contact:
Mr. George Owoo
President and CEO
764 Porter Circle, Lindenhurst, IL 60046
Email:owoog@welgrace.com
Telephone 224-372-7918, 908-295-1985 FAX 224-372-7464
Mr. George Owoo
President and CEO
764 Porter Circle, Lindenhurst, IL 60046
Email:owoog@welgrace.com
Telephone 224-372-7918, 908-295-1985 FAX 224-372-7464
